BioNTech (NASDAQ:BNTX) Given New $124.00 Price Target at JPMorgan Chase & Co.

BioNTech (NASDAQ:BNTX) had its target price trimmed by JPMorgan Chase & Co. from $125.00 to $124.00 in a research report released on Monday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

BNTX has been the subject of several other reports. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and increased their price objective for the company from $96.00 to $150.00 in a report on Tuesday, September 17th. HC Wainwright increased their price target on BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. HSBC boosted their price objective on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. Five investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $134.69.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $107.88 on Monday. The company has a market capitalization of $25.65 billion, a P/E ratio of -51.37 and a beta of 0.26. The company’s 50-day moving average is $111.40 and its 200 day moving average is $96.39. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.34%. The firm had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the previous year, the company earned $0.73 earnings per share. The company’s quarterly revenue was up 38.9% on a year-over-year basis. On average, equities research analysts forecast that BioNTech will post -2.93 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

Several large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its stake in BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after acquiring an additional 111 shares during the last quarter. Covestor Ltd increased its position in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares during the last quarter. Midwest Professional Planners LTD. raised its stake in BioNTech by 7.2% in the first quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after purchasing an additional 212 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in BioNTech by 2.3% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock valued at $904,000 after purchasing an additional 223 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after buying an additional 252 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.